China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; and other dosage forms, including pills and tablets; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, chronic illnesses, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products. The company was incorporated in 2002 and is headquartered in Shijiazhuang, China. China Shineway Pharmaceutical Group Limited operates as a subsidiary of Forway Investment Limited.
Research context
China Shineway Pharmaceutical Group Limited appears in PyInvesting’s Hong Kong Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
China Shineway Pharmaceutical Group Limited is currently in a long term uptrend where the price is trading 27.5% above its 200 day moving average.
From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
China Shineway Pharmaceutical Group Limited's total revenue rose by 9.6% to $1B since the same quarter in the previous year.
Its net income has dropped by 80.8% to $41M since the same quarter in the previous year.
Finally, its free cash flow grew by 931.6% to $171M since the same quarter in the previous year.
Based on the above factors, China Shineway Pharmaceutical Group Limited gets an overall score of 4/5.